{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ji Z"],"funding":["Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch","Tianjin Science and Technology Commission key project","PhD Start-up Foundation of Tianjin Medical University Cancer Institute and Hospital","Tianjin Key Medical Discipline (Specialty) Construction Project"],"pagination":["e010041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11629098"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["Background
Perioperative chemotherapy is the standard of care for patients with locally advanced gastric and gastroesophageal junction cancer. Recent evidence demonstrated the addition of programmed cell death protein 1 (PD-1) inhibitors enhanced therapeutic efficacy. However, the mechanisms of response and resistance remain largely undefined. A detailed multiomic investigation is essential to elucidate these mechanisms.Methods
We performed whole-exome sequencing, whole-transcriptome sequencing, multiplex immunofluorescence and single-cell RNA sequencing on matched pretreatment and post-treatment samples from 30 patients enrolled in an investigator-initiated Phase 2 clinical trial (NCT04908566). All patients received neoadjuvant PD-1 inhibitors in combination with chemother"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy."],"pmcid":["PMC11629098"],"funding_grant_id":["WKZX2024CX102217","B1806","TJYXZDXK-009A","21JCZDJC00980","B2204"],"pubmed_authors":["Li H","Deng T","Ma L","Lv X","Ba Y","Su L","Liu R","Zhang L","Xin J","Ge S","Liu Y","Zuo D","Zhang Y","Ding T","Ji Z","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.","description":"Background
Perioperative chemotherapy is the standard of care for patients with locally advanced gastric and gastroesophageal junction cancer. Recent evidence demonstrated the addition of programmed cell death protein 1 (PD-1) inhibitors enhanced therapeutic efficacy. However, the mechanisms of response and resistance remain largely undefined. A detailed multiomic investigation is essential to elucidate these mechanisms.Methods
We performed whole-exome sequencing, whole-transcriptome sequencing, multiplex immunofluorescence and single-cell RNA sequencing on matched pretreatment and post-treatment samples from 30 patients enrolled in an investigator-initiated Phase 2 clinical trial (NCT04908566). All patients received neoadjuvant PD-1 inhibitors in combination with chemother","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-02T04:38:37.76Z","creation":"2025-04-19T14:37:35.391Z"},"accession":"S-EPMC11629098","cross_references":{"pubmed":["39653554"],"doi":["10.1136/jitc-2024-010041"]}}